|
|
Volumn 96, Issue 20, 2004, Pages 1495-1496
|
|
Accelerated approval seen as triumph and roadblock for cancer drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTIRETROVIRUS AGENT;
CAPECITABINE;
DOCETAXEL;
GEFITINIB;
IMATINIB;
IRINOTECAN;
MOLECULAR MARKER;
OXALIPLATIN;
PLACEBO;
RAZOXANE;
NEW DRUG;
TUMOR MARKER;
ACCURACY;
CANCER PATIENT;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLON CANCER;
DATA ANALYSIS;
DISEASE MARKER;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
EVIDENCE BASED MEDICINE;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE ACCESS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LUNG CANCER;
MEDICAL DECISION MAKING;
MEDICAL SPECIALIST;
METASTASIS;
NOTE;
ONCOLOGY;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
UNITED STATES;
VALIDATION PROCESS;
BIOASSAY;
CONTROLLED CLINICAL TRIAL;
DRUG SCREENING;
ORGANIZATION AND MANAGEMENT;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
TIME;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE III;
DRUG APPROVAL;
DRUG SCREENING ASSAYS, ANTITUMOR;
DRUGS, INVESTIGATIONAL;
ENDPOINT DETERMINATION;
HUMANS;
RANDOMIZED CONTROLLED TRIALS;
TIME FACTORS;
TUMOR MARKERS, BIOLOGICAL;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 6944244889
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/96.20.1495 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|